Novel mechanism of action for hydralazine: Induction of hypoxia-inducible factor-1 α, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases

Circulation Research

Volumn 95, Issue 2, 2004, Pages 162-169

  Knowles, Helen J ^a   Tian, Ya Min ^b   Mole, David R ^b   Harris, Adrian L ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cardiovascular disease; Endothelial cells; Iron chelation; Ischemia

Indexed keywords

ADRENOMEDULLIN; CALCIUM; ENDOTHELIN 1; HEME OXYGENASE 1; HYDRALAZINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; TISSUE EXTRACT; VASCULOTROPIN; VASODILATOR AGENT;

ANGIOGENESIS; ANIMAL TISSUE; ARTERY MUSCLE; ARTICLE; BLOOD LEVEL; BLOOD VESSEL DENSITY; CALCIUM CELL LEVEL; CAPILLARY DENSITY; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; ISCHEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN STABILITY; SMOOTH MUSCLE FIBER; VASODILATATION;

ADRENOMEDULLIN; ANGIOGENESIS INDUCING AGENTS; ANIMALS; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, RENAL CELL; CELL HYPOXIA; CELL LINE, TUMOR; CELLS, CULTURED; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIN-1; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HEME OXYGENASE (DECYCLIZING); HEME OXYGENASE-1; HUMANS; HYDRALAZINE; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMPLANTS, EXPERIMENTAL; KIDNEY NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MYOCYTES, SMOOTH MUSCLE; NEOVASCULARIZATION, PHYSIOLOGIC; NUCLEAR PROTEINS; PEPTIDES; PROCOLLAGEN-PROLINE DIOXYGENASE; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASODILATOR AGENTS;

EID: 3342955379     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000134924.89412.70     Document Type: Article

References (48)

1. Gomberg-Maitland M, Baran DA, Fuster, V. Treatment of congestive heart failure: guidelines for the primary care physician and the heart failure specialist. Arc Intern Med. 2001;161:342-352.
2. Duley L, Henderson-Smart DJ. Drugs for treatment of very high blood pressure during pregnancy (Cochrane Review). Cochrane Database Syst Rev. 2002;CD001449.
3. Ellershaw DC, Gurney AM. Mechanisms of hydralazine induced vasodilation in rabbit aorta and pulmonary artery. Br J Pharmacol. 2001; 134:621-631.
4. Jacobs M. Mechanism of action of hydralazine on vascular smooth muscle. Biochem Pharmacol. 1984;33:2915-2919.
5. + channels. Eur J Pharmacol. 1998;361:43-49.
6. Hermsmeyer K, Trapani A, Abel PW, Worcel M. Effect of hydralazine on tension and membrane potential in the rat caudal artery. J Pharmacol Exp Ther. 1983;227:322-326.
7. Wei S, Kasuya Y, Yanagisawa M, Kimura S, Masaki T, Goto K. Studies on endothelium-dependent vasorelaxation by hydralazine in porcine coronary artery. Eur J Pharmacol. 1997;321:307-314.
8. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flofr KH et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547-1552.
9. Gogia H, Mehra A, Parikh S, Raman M, Ajit-Uppal J, Johnson JV, Elkayam U. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol. 1995;26:1575-1580.
10. Munzel T, Kurz S, Rajagopalan S, Thoenes M, Berrington WR, Thompson JA, Freeman BA, Harrison DG. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase-a new action for an old drug. J Clin Invest. 1996; 98:1465-1470.
11. Bhatnagar RS, Rapaka SSR, Liu TZ, Wolfe SM. Hydralazine-induced disturbances in collagen biosynthesis. Biochim Biophys Acta. 1972; 271:125-132.
12. Murad S, Tajima S, Pinnell SR. A paradoxical effect of hydralazine on prolyl and lysyl hydroxylase activities in cultured human skin fibroblasts. Arch Biochem Biophys. 1985;241:356-363.
13. Epstein ACR, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. C. elegans EGL-9 and mammalian homologues define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107:42-54.
14. Bruick KB, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294:1337-1340.
15. Semenza GL. Hypoxia-inducible factor 1: control of oxygen homeostasis in health and disease. Pediat Res. 2001;49:614-617.
16. 2-regulated prolyl hydroxylation. Science. 2001;292:468-472.
17. D'Angelo G, Duplan E, Boyer N, Vigne P, Frelin C. Hypoxia up-regulates prolyl hydroxylase activity. A feedback mechanism that limits HIF-1 responses during reoxygenation. J Biol Chem. 2003;278: 38183-38187.
18. Reece PA, Cozamanis I, Zacest R. Kinetics of hydralazine and its main metabolites in slow and fast acetylators. Clin Pharmacol Ther. 1980;28:769-778.
19. Sim E, Payton M, Noble M, Minchin R. An update on genetic, structural and functional studies on arylamine N-acetyltransferases in eucaryotes and procaryotes. Human Mol Genet. 2000;9:2435-2441.
20. Minchenko A, Bauer T, Salceda S, Caro J. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest. 1994;71:374-379.
21. Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci U S A. 1998;95:15809-15814.
22. Al-Falahi H, May PM, Roe AM, Slater RA, Trott WJ, Williams DR. Metal-binding by pharmaceuticals. Part 4. A comparative investigation of the interaction of metal ions with hydralazine, prizidilol and related compounds. Agents Actions. 1984;14:113-120.
23. Palmer LA, Semenza GL, Stoler MH, Johns RA. Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. Am J Physiol. 1998;274:L212-L219.
24. Gattullo D, Pagliaro P, Marsh NA, Losano G. New insights into nitric oxide and coronary circulation. Life Sci. 1999;65:2167-2174.
25. Saito S, Hirata Y, Imai T, Marumo F. Autocrine regulation of the endothelin-1 gene in rat endothelial cells. J Cardiovasc Pharmacol. 1995;26:S84-S87.
26. Hartsfield CL, Alam J, Cook JL, Choi AMK. Regulation of heme oxygenase-I gene expression in vascular smooth muscle cells by nitric oxide. Am J Physiol. 1997;273:L980-L988.
27. Le NTV, Richardson DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta. 2002; 1603:31-46.
28. Fisker RV, Horsman MR, Overgaard J. Hydralazine-induced changes in tissue perfusion and radiation response in a C3H mammary carcinoma and mouse normal tissues. Acta Oncologica. 1991;30: 641-647.
29. Honess DJ, Bleehen NM. Comparative effects of hydralazine on perfusion of KHT tumour, kidney and liver and renal function in mice. Int J Radiat Oncol Biol Phys. 1992;22:953-961.
30. Leier CB, Magorien RD, Desch CE, Thompson MJ, Unverferth DV. Hydralazine and isosorbide dinitrate: comparative central and regional haemodyamic effects when administered alone or in combination. Circulation. 1981;634:102-109.
31. Oehler MK, Hague S, Rees MCP, Bicknell R. Adrenomedullin promotes formation of xenografted endometrial tumours by stimulation of autocrine growth and angiogenesis. Oncogene. 2002;21: 2815-2821.
32. Salani D, Taraboletti G, Rosano L, Di Castro V, Borsotti P, Giavazzi R, Bagnato A. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularisation in vivo. Am J Path. 2000;157:1703-1711.
33. Farrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol. 2002;29:S10-S14.
34. Deramaudt BMJM, Braunstein S, Remy P, Abraham NG. Gene transfer of human haem oxygenase into coronary endothelial cells potentially promotes angiogenesis. J Cell Biochem. 1998;68:121-127.
35. Ali N, Yousufzai SYK, Abdel-Latif AA. Activation of particulate guanylate cyclase by adrenomedullin in cultured SV-40 transformed cat iris sphincter smooth muscle (SV-CISM-2) cells. Cellular Signalling. 2000;12:491-498.
36. Duckers HJ, Boehm M, Trye AL, Yet SF, San H, Park JL, Webb CR, Lee ME, Nabel GJ, Nabel EG. Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med. 2001;7:693-698.
37. Ding K-H, Latimer AJ, Abdel-Latif AA. Activation of particulate guanylate cyclase by endothelins in cultured SV-40 transformed cat iris sphincter smooth muscle cells. Life Sci. 1999;64:161-174.
38. Kroll J, Waltenberger J. A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells. Biochem Biophys Res Commun. 1999;30:636-639.
39. Toppozada MK, Darwish E, Barakat AA. Management of severe preeclampsia detected in early labor by prostaglandin Al or dihydralazine infusions. Am J Obstet Gynecol. 1991;164:1229-1232.
40. Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DAH, Bauer C, Gassmann M, Candinas D. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J. 2001;15:2445-2453.
41. Yu AY, Frid MG, Shimoda LA, Wiener CM, Stenmark K, Semenza GL. Temporal, spatial and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am J Physiol. 1998;275:L818-L826.
42. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases. The role of oxidant stress. Circ Res. 2000;87:840-844.
43. Rehse K, Shahrouri T. New NO donors with antithrombotic and vasodilating activities, part 24. Hydrazine derivatives. Arch Pharm Pharm Med Chem. 1998;331:308 -312.
44. Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Simons M, Losordo DW, Hendel RC, Bonow RO, Eppler SM, Zioncheck TF, Holmgren EB, McCluskey ER. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J. 2001;142:872-880.
45. Nagaya N, Goto Y, Satoh T, Sumida H, Kojima S, Miyatake K, Kangawa K. Intravenous adrenomedullin in myocardial function and energy metabolism in patients after myocardial infarction. J Cardiovasc Pharmacol. 2002;39:754-760.
46. Chao J, Kato K, Zhang JJ, Dobrzynski E, Wang C, Agata J, Chao L. Human adrenomedullin gene delivery protects against cardiovascular remodelling and renal injury. Peptides. 2001;22:1731-1737.
47. Elson DA, Thurston G, Huang LE, Ginzinger DG, McDonald DM, Johnson RL, Arbeit JM. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1α. Genes Dev. 2001;15:2520-2532.
48. Pfander D, Cramer T, Schipani E, Johnson RS. HIF-1 alpha controls extracellular matrix synthesis by epiphyseal chondrocytes. J Cell Sci. 2003;116:1819-1826.